|
 According to an update on the website clinicaltrials.gov, run by the
U.S. National Institutes of Health, the so-called ARCTIC study is
now due to complete on Nov. 15. AstraZeneca had previously said it
expected results in the first half of 2017.
A company spokeswoman said the delay was because the trial had not
yet observed enough clinical events in patients.
"This trial, like most other oncology trials, is event-driven so it
is not unusual for the timeline to change slightly," she said.
The Phase III ARCTIC study is testing whether durvalumab on its own
or in combination with tremelimumab can increase overall survival or
delay the time it takes for lung cancer to worsen, when given as a
third-line treatment.
The durva/treme drug cocktail is viewed as a potential
multibillion-dollar market opportunity for AstraZeneca. However, the
number of patients who might receive third-line treatment is
relatively small.
[to top of second column] |
Investor attention is focused primarily on giving the drug
combination to previously untreated, or first-line, patients.
Results from the closely watched MYSTIC trial in this much larger
patient group are expected mid-year.
(Reporting by Ben Hirschler; Editing by Adrian Croft)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
